T he article by Kuh and colleagues 1 appearing in this issue of Circulation relates biomarkers of cardiovascular disease risk and end-organ damage to declines in physical capacity in 1736 British 60-to 64-year-olds. This article is notable for 2 reasons. The dependent variables it considers are related to physical function, not cardiovascular function; and it provides the opportunity to place cardiovascular disease in the context of an emerging geroscience paradigm which holds that the occurrence of age-associated diseases including cardiovascular disease is attributable, in part, to fundamental aging biology. Its overarching hypothesis is that agerelated disease can be delayed by intervening in aging biology, a strategy that is distinct from the current approach, which focuses on specific pathways to prevent specific diseases.
strength of the association with cystatin C. Nevertheless, measures of end-organ distress and inflammation are clearly associated with faster declines in physical performance in adults in their early 60s, even accounting for prevalent clinically manifest cardiorenal disease and standard cardiovascular disease risk factors. Although there have been similar previous reports for IL-6 and cystatin C, this is the first study to link NT-proBNP to physical function in such a way. The BIOSTAT-CHF study (Systems Biology Study to Tailored Treatment in Chronic Heart Failure) recently reported that baseline NT-proBNP levels were associated with 6-minute walk distance in heart failure patients, who differ markedly from the community-dwelling population considered here. 3 The median levels measured by Kuh et al were quite low (55 pg/mL) and many-fold lower than those seen in heart failure, and the relationship with function was linear across the observed range, suggesting that this measure is not a proxy for undiagnosed heart failure.
Grip strength, walking speed, balance, and the ability to rise from a chair are measures of physical capacity. The term physical capacity deserves some elaboration. Nagi 4 proposed a model to help study the trajectories of functional decline. In this model, disease pathology "impairs" organ function. Sufficient impairment leads to "limitation" reflected in difficulty in performing activities. Severe limitations can result in "disability" or the inability to perform tasks independently. The World Health Organization proposed an expanded model which denominates "body structures and functions" that support the performance of "activities" which, in turn, permit "participation" in and fulfillment of social roles (as a less pejorative framing than "disability"). 5 Why should cardiovascular disease researchers be concerned with physical capacity? Quoting a 2017 American Heart Association scientific statement, "Adults are living longer, and cardiovascular disease is endemic in the growing population of older adults who are surviving into old age. Functional capacity is a key metric in this population, both for the perspective it provides on aggregate health and as a vital goal of care." 6 This deserves amplification. Research across a variety of medical subspecialties has shown that measures of physical function predict care outcomes beyond measures related to a specific organ or organ system. 7 The interpretation of disease risk factors can differ by functional status as can the odds of treatment success. Gait speed, in particular, predicts mortality and complications in patients with various kinds of heart disease beyond ejection fraction or other cardiovascular specific metrics. Furthermore, physical and cognitive functional capacity are at the core of living independently, which many older patients value above life itself. 8 Thus, anyone treating an older patient should be prepared to discuss prospective treatments with respect to their likelihood of risk and benefits to functional capacity.
Walking and other physical functions are not the domain of any single subspecialty. Walking speed not only reflects the cardiovascular system but also is affected by mood, anemia, lower extremity pain, strength, obesity, and peripheral neuropathy. 7 Maneuvers that restore the function of a single organ may not improve physical capacity. In 1 series, 28% of patients undergoing transcatheter aortic valve replacement realize no functional benefit from the procedure as reflected by 6-minute walk time. 9 Perhaps having a fuller understanding of how all the contributors to functional capacity interact could help better predict whether a given older patient's function is likely to benefit from a procedure targeting the heart.
After midlife, physical capacity declines, a process that accelerates late in life. This observation is not unique to humans. The loss of speed is a hallmark of aging in virtually all mammalian species. Until relatively recently, most believed that aging was immutable. Advances in the biology of aging have shown this not to be true; lifespan can be extended by genetic manipulation, by restricting energy intake, or by pharmacological means in multiple animal models. 10 As animals live longer, the onset of chronic diseases is also delayed, and in the case of caloric restriction, physical function is also maintained. This observation has inspired a new field, geroscience, which seeks to improve human health through targeting the biology of aging. The hope is that by targeting aging biology, one can simultaneously slow multiple age-related diseases, including cancer, cardiovascular disease, and Alzheimer disease. This is distinct from the current model of preventing disease, which is based on identifying specific pathways to specific diseases and developing interventions targeting these pathways. Demographers have shown that this strategy will have a limited impact on societal disease burden because delaying 1 disease still exposes one to the exponentially increasing risks of all other agerelated diseases. Currently, pharmaceutical agents including metformin and analogs of rapamycin are being considered for human trials to test this idea. 11, 12 How does one select end points to show that the biology of aging has been affected without following thousands of people for several years to observe rates of incident disease and death? There is a great deal of effort being devoted to identifying potential blood-based biomarkers that might serve as plausible indicators of the aging process for use in such trials. Of relevance to this discussion, IL-6, cystatin C, and NT-proBNP have all been proposed as potential trial biomarkers. 13 All 3 increase with age, predict mortality and function across their entire ranges, and have been shown to be responsive to intervention. NT-proBNP is produced by the stressed heart and has been shown to be related to the risk of a number of different cardiovascular disease outcomes, including heart failure, myocardial infarction, sudden cardiac death, and arrhythmia, but its consideration as a potential aging biomarker is new. Intriguingly, recent data from the PLATO biomarkers study (Platelet Inhibition and Patient Outcomes trial) found that a 1-log-unit SD difference in baseline NT-proBNP was related to a 2.21-fold increase in the rate of nonvascular mortality in patients with acute coronary syndromes. 14 Thus, it is possible that the relationships with the biomarkers measured by Kuh and colleagues and function may reflect underlying biological age, which would also be reflected in diminished physical capacity.
As a researcher who started his career in cardiovascular epidemiology and has since migrated to aging research, I find the paper by Kuh and colleagues wonderful to see. It touches on 2 themes of growing importance: the role of physical function assessment in cardiovascular research, and the place of cardiovascular pathophysiology in the context of organismal aging. One hopes that this paper is an indicator of increasing attention toward these important themes within the cardiovascular research community.
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